IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, today announced that it has won a global Phase 3 clinical trial contract in Huntington’s disease (HD) with an international biotechnology company. The contract is worth £2.7million in revenues to IXICO over the next six years.
This is the second Phase 3 HD contract that IXICO has been awarded over the past 12 months, reinforcing its position as a trusted partner to biopharma companies as an increasing number of innovative new therapies in HD advance to late stage clinical trials and potential FDA approval. The news follows the announcement in late October of two contract wins in Alzheimer’s Disease (AD) and sees a continuation of IXICO’s revenue growth momentum and order book expansion.
Bram Goorden, CEO of IXICO, commented: “We are proud to be working at the cutting edge of innovative therapies, helping biopharmaceutical companies advance potentially transformative treatments for patients and families affected by Huntington’s disease. This contract is another strong endorsement of IXICO’s leading position in the neurodegenerative disease field. It also demonstrates our continued progress in strengthening our order book through an increasing contribution from later-stage clinical trials, providing long-term revenue visibility and supporting our growth ambitions.”
